doi: 10.3390/ani12151981, 140
Semaglutide (aka Ozempic or Wegovy) has become ubiquitous because of established benefits in diabetes and obesity but SELECT showed that the wonder drug should be considered in those who are obese with established atherosclerotic CV disease (ASCVD.) In March of 2024 the FDA approved a new indication for Wegovy based on the SELECT trial to reduce the risk of CV death, stroke, and heart attack in adults with cardiovascular disease and either obese or overweight Lets take a look at the group SELECT enrolled to see if you or the patient in front of you is similar to those enrolled
Avoid greasy, fried, or highly processed foods: Fatty foods take longer to digest and can worsen nausea
An der Studie nahmen 2.900 Teilnehmer teil und untersuchten den Einfluss einer L-Carnitin-Supplementierung auf glykmische Marker bei Patienten mit Diabetes
The purchaser accepts full responsibility for lawful handling, storage, and application of this material
With new technology and techniques, compounding pharmacists are able to make customized medications to meet the specific needs of their patients